Wisevoter
U.S.

Integra LifeSciences Enrolled 100th Pediatric Patient

The AERA Pediatric Registry has reached a milestone in tracking Eustachian tube balloon dilation system outcomes.

Updated on Sept. 29, 2026 in Allergies

Bold flat-color editorial illustration depicting a stylized medical device, evoking clinical research data and systematic patient tracking.
Integra LifeSciences announced on Tuesday that it has enrolled 100 patients in its AERA Pediatric Registry, an ongoing study evaluating the performance of its Eustachian tube balloon dilation device. AI Illustration. Upload story photo >

Live Poll

Does real-world registry data from medical companies increase your trust in new medical devices?

Integra LifeSciences has officially enrolled the 100th patient into the AERA Pediatric Registry. This ongoing study evaluates the clinical performance of the Acclarent AERA Eustachian Tube Balloon Dilation System in children aged eight and older.

Why it matters

The registry aims to generate essential real-world evidence for the safety and effectiveness of the device in treating pediatric patients with obstructive Eustachian tube dysfunction. It provides critical data on a specialized treatment pathway for children.

The AERA Pediatric Registry tracks clinical performance for children aged eight or older, with 100 patients currently enrolled. The study plans to reach a total of 300 pediatric participants.

The players

Integra LifeSciences

A global medical technology company headquartered in Princeton, N.J., that specializes in surgical and medical devices.

The details

This multicenter observational study is conducted across clinical sites throughout the United States to monitor the use of the Acclarent AERA system. The company aims to collect data on how the balloon dilation device performs in pediatric care settings for obstructive conditions.

Timeline

  1. December 2023: The AERA system received FDA clearance for pediatric use.

  2. July 2025: The AERA Pediatric Registry officially launched.

  3. September 29, 2026: The 100th patient was enrolled in the registry.

The Big Picture

This registry follows the regulatory pathway established by the FDA pediatric clearance for the Acclarent AERA Eustachian Tube Balloon Dilation System. It extends that initial approval by gathering ongoing real-world data to validate the treatment's performance in younger populations.

The registry focuses on gathering evidence that may eventually inform broader treatment protocols for children suffering from obstructive Eustachian tube dysfunction. Families of children aged eight or older may see this research influence how doctors approach minimally invasive tube dilation options in the future.

The takeaway

Ongoing observational studies are crucial for expanding medical device indications to younger populations where clinical data is often limited. Parents should consult with their healthcare providers regarding the latest clinical evidence when considering procedural interventions for chronic ear conditions.

Further reading

For more on evolving standards for pediatric care and related conditions, visit the Allergies section.

Source note: This article includes information reported by The Manila times.

Live Poll

Does real-world registry data from medical companies increase your trust in new medical devices?